Literature DB >> 25052379

Macrophage density and macrophage colony-stimulating factor expression predict the postoperative prognosis in patients with intrahepatic cholangiocarcinoma.

Kosuke Oishi1, Takanori Sakaguchi, Satoshi Baba, Shohachi Suzuki, Hiroyuki Konno.   

Abstract

PURPOSES: Macrophages are included in the stromal compartments in various neoplasms, and their behavior against tumors is diverse. The aim of this study was to examine the role of tumor-infiltrating macrophages and their main regulator, macrophage colony-stimulating factor (M-CSF), in intrahepatic cholangiocarcinoma (ICC).
METHODS: Macrophage density and M-CSF expression in 39 resected ICC specimens were immunohistochemically evaluated in the central and peripheral areas of tumors, which were defined as fields more than and within 500 μm from the invasive front, respectively. The number of CD68-positive macrophages was counted using an image-analyzing software program. The relationship between these results and other clinicopathological factors and the postoperative prognosis were evaluated.
RESULTS: Sporadic M-CSF expression in cancer cells around the peripheral area was observed in fourteen patients. M-CSF-positive ICCs showed a higher macrophage density in the tumor-peripheral area than did M-CSF-negative ICCs. M-CSF expression and higher macrophage density in the tumor-peripheral area were related to a better postoperative prognosis, whereas a higher macrophage density in the central area was one of the significant risk factors for a poor prognosis in a univariate analysis.
CONCLUSION: Tumor-peripheral macrophage infiltration, presumably dependent on M-CSF, and M-CSF-independent tumor-central macrophage infiltration are predictive factors for better and worse postoperative prognosis in ICC patients, respectively. The tumor microenvironment, such as the presence of hypoxia, may affect the behavior of infiltrating macrophages in ICC.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25052379     DOI: 10.1007/s00595-014-0989-y

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  36 in total

1.  Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL).

Authors:  Daisuke Niino; Yoshihiro Komohara; Toshihiko Murayama; Ryosuke Aoki; Yoshizo Kimura; Keiko Hashikawa; Junichi Kiyasu; Masanori Takeuchi; Nobuko Suefuji; Yasuo Sugita; Motohiro Takeya; Koichi Ohshima
Journal:  Pathol Int       Date:  2010-04       Impact factor: 2.534

2.  Differential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis.

Authors:  Norihiko Takeda; Ellen L O'Dea; Andrew Doedens; Jung-whan Kim; Alexander Weidemann; Christian Stockmann; Masataka Asagiri; M Celeste Simon; Alexander Hoffmann; Randall S Johnson
Journal:  Genes Dev       Date:  2010-03-01       Impact factor: 11.361

3.  Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma.

Authors:  Horlad Hasita; Yoshihiro Komohara; Hirohisa Okabe; Toshiro Masuda; Koji Ohnishi; Xiao F Lei; Toru Beppu; Hideo Baba; Motohiro Takeya
Journal:  Cancer Sci       Date:  2010-05-12       Impact factor: 6.716

4.  High macrophage infiltration along the tumor front correlates with improved survival in colon cancer.

Authors:  Johan Forssell; Ake Oberg; Maria L Henriksson; Roger Stenling; Andreas Jung; Richard Palmqvist
Journal:  Clin Cancer Res       Date:  2007-03-01       Impact factor: 12.531

5.  The macrophage colony-stimulating factor 1 response signature in breast carcinoma.

Authors:  Andrew H Beck; Inigo Espinosa; Badreddin Edris; Rui Li; Kelli Montgomery; Shirley Zhu; Sushama Varma; Robert J Marinelli; Matt van de Rijn; Robert B West
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

6.  High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma.

Authors:  Xiao-Dong Zhu; Ju-Bo Zhang; Peng-Yuan Zhuang; Hong-Guang Zhu; Wei Zhang; Yu-Quan Xiong; Wei-Zhong Wu; Lu Wang; Zhao-You Tang; Hui-Chuan Sun
Journal:  J Clin Oncol       Date:  2008-06-01       Impact factor: 44.544

7.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

Authors:  Tania M Welzel; Barry I Graubard; Hashem B El-Serag; Yasser H Shaib; Ann W Hsing; Jessica A Davila; Katherine A McGlynn
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 11.382

8.  Tumor infiltrating macrophages reduce development of peritoneal colorectal carcinoma metastases.

Authors:  Gerben J van der Bij; Marijn Bögels; Steven J Oosterling; Jeffrey Kroon; Dénise T M Schuckmann; Helga E de Vries; Sybren Meijer; Robert H J Beelen; Marjolein van Egmond
Journal:  Cancer Lett       Date:  2008-01-09       Impact factor: 8.679

9.  Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas.

Authors:  Y Komohara; K Ohnishi; J Kuratsu; M Takeya
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

10.  M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma.

Authors:  Bicheng Zhang; Guoqing Yao; Yafei Zhang; Juan Gao; Bo Yang; Zhiguo Rao; Jianfei Gao
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

View more
  8 in total

1.  Improved surgical outcomes for hilar cholangiocarcinoma: changes in surgical procedures and related outcomes based on 40 years of experience at a single institution.

Authors:  Ryota Higuchi; Takehiro Ota; Takehisa Yazawa; Hideki Kajiyama; Tatsuo Araida; Toru Furukawa; Tatsuya Yoshikawa; Ken Takasaki; Masakazu Yamamoto
Journal:  Surg Today       Date:  2015-02-05       Impact factor: 2.549

2.  Tumor necrosis and infiltrating macrophages predict survival after curative resection for cholangiocarcinoma.

Authors:  Georgi Atanasov; Corinna Dietel; Linda Feldbrügge; Christian Benzing; Felix Krenzien; Andreas Brandl; Elli Mann; Julianna Paulina Englisch; Katrin Schierle; Simon C Robson; Katrin Splith; Mehmet Haluk Morgul; Anja Reutzel-Selke; Sven Jonas; Andreas Pascher; Marcus Bahra; Johann Pratschke; Moritz Schmelzle
Journal:  Oncoimmunology       Date:  2017-06-28       Impact factor: 8.110

3.  Isolation of Mouse and Human Tumor-Associated Macrophages.

Authors:  Luca Cassetta; Roy Noy; Agnieszka Swierczak; Gaël Sugano; Harriet Smith; Lisa Wiechmann; Jeffrey W Pollard
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

4.  Tumor-associated macrophages recruited by periostin in intrahepatic cholangiocarcinoma stem cells.

Authors:  Jiehong Zeng; Zhengkai Liu; Shuwen Sun; Jianhong Xie; Li Cao; Pin Lv; Shengdan Nie; Bao Zhang; Bowen Xie; Siyuan Peng; Bo Jiang
Journal:  Oncol Lett       Date:  2018-03-29       Impact factor: 2.967

5.  The impact of inflammatory cells in malignant ascites on small intestinal ICCs' morphology and function.

Authors:  Jing Li; Dan Kong; Yan He; Xiuli Wang; Lei Gao; Jiade Li; Meisi Yan; Duanyang Liu; Yufu Wang; Lei Zhang; Xiaoming Jin
Journal:  J Cell Mol Med       Date:  2015-06-18       Impact factor: 5.310

Review 6.  Nanomedicine Strategies to Target Tumor-Associated Macrophages.

Authors:  Karin Binnemars-Postma; Gert Storm; Jai Prakash
Journal:  Int J Mol Sci       Date:  2017-05-04       Impact factor: 5.923

7.  PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome.

Authors:  Lingyu Tian; Jiaqiang Ma; Lijie Ma; Bohao Zheng; Longzi Liu; Danjun Song; Yining Wang; Zhao Zhang; Qiang Gao; Kang Song; Xiaoying Wang
Journal:  World J Surg Oncol       Date:  2020-11-23       Impact factor: 2.754

Review 8.  The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium.

Authors:  Alessandra Gentilini; Mirella Pastore; Fabio Marra; Chiara Raggi
Journal:  Int J Mol Sci       Date:  2018-09-22       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.